PR Newswire - CStone Announces European Medicine Agency CHMP Rec...
EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demonstrating significant progression-free survival (PFS) and overall survival (OS) benefits of sugemalima...
Read More

ภาษาไทย
English